EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Kontrollierte klinische StudieMultizentrische StudieOpen Access

Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers

Julian Biau, Xushan Sun, Xavier Liem, Jean-Christophe Faivre, Elife Eker, Pierre Blanchard, Yungan Tao, Mélanie Doré, Philippe Maingon, Noémie Vulquin, Marc Alfonsi, Sebastien Thureau und 11 weitere

JAMA Network Open · 18.12.2025 · 8 (12) · e2549975

DOI: 10.1001/jamanetworkopen.2025.49975 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JAMA Network Open, online erschienen am 18.12.2025. Verfasst von Julian Biau und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Mouth Neoplasms, Oropharyngeal Neoplasms, Radiosurgery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Postoperative radiotherapy (mainly fractionated intensity-modulated radiotherapy) is indicated after surgery for early-stage oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC) in the presence of high-risk margins. Postoperative brachytherapy is a treatment option, but it is not always feasible; stereotactic body radiotherapy (SBRT) may offer a noninvasive alternative.

Objective

To evaluate late toxic effects and 2-year local control after postoperative SBRT to the primary tumor bed in patients with early-stage OCSCC or OPSCC and high-risk resection margins. Design, Setting, and Participants This national, multicenter, single-arm, phase 2 nonrandomized clinical trial was conducted across 18 academic centers in France in the Groupe d’Oncologie Radiothérapie Tête et Cou (GORTEC) network. Adults with pT1 to pT2 OCSCC or OPSCC and R1 or smaller than 5 mm margins, pN0 or pN1 without extracapsular extension, no indication for neck irradiation, and not planned for adjuvant chemotherapy were enrolled between April 2018 and August 2021. Final analysis was conducted from February to May 2024.

Intervention

SBRT to the surgical bed, 36 Gy in 6 fractions over 2 weeks, using volumetric modulated arctherapy (VMAT) or CyberKnife, with image guidance and quality assurance protocols. Main Outcomes and Measures The primary outcome was the 2-year rate of grade 3 or greater late toxic effects (>90 days after treatment), per Common Terminology Criteria for Adverse Events version 4.03. The key secondary end point was 2-year local control. Quality of life (QoL) was assessed using European Organization for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire Head and Neck Module (QLQ-HN35).

Results

Among 90 patients (median [range] age, 64 [31-87] years; 51 [56.5%] male), at 2 years, 2 patients (2.2%) had grade 3 late toxic effects, while 13 patients (14.6%) experienced at least 1 grade 3 late toxic effect during the 2-year follow-up period, mainly soft-tissue necrosis and osteoradionecrosis, most of which were transitory. The 2-year local control rate was 92.0% (95% CI, 84.6%-96.4%). Acute grade 3 or greater toxic effects were limited to mucositis (28.9%; 95% CI, 19.8%-39.4%), mostly resolving by 3 months. Median follow-up was 25 months (range, 3-31 months). Disease-free and overall survival at 2 years were 73.3% (95% CI, 63.4%-81.7%) and 88.8% (95% CI, 80.9%-94.2%), respectively. QoL scores showed a transient decline at 1 month followed by recovery and improvement at 12 and 24 months. Conclusions and Relevance In this phase 2 nonrandomized clinical trial, postoperative primary tumor bed SBRT for early-stage OCSCC and OPSCC with high-risk margins was associated with manageable toxic effects and high rates of local control. These findings support SBRT as a promising approach in carefully selected patients, but confirmatory randomized trials are needed. Trial Registration ClinicalTrials.gov Identifier: NCT03401840

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsOropharyngeal NeoplasmsRadiosurgeryAgedFemaleHumansMaleMiddle AgedFranceNeoplasm StagingQuality of Life

Autor:innen und Institutionen

  • Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
  • INSERM U1240 IMoST, Université Clermont Auvergne, Clermont-Ferrand, France.
  • UMR 501, Centre d'Investigation Clinique, Clermont-Ferrand, F-63001 France.
  • Department of Radiation Oncology, Hôpital Nord Franche-Comté and CHRU Besançon, Montbéliard and Besançon, France.
  • Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.
  • Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France.

Zitieren

APA

Biau, J., Sun, X., Liem, X., Faivre, J. C., Eker, E., Blanchard, P., Tao, Y., Doré, M., Maingon, P., Vulquin, N., Alfonsi, M., Thureau, S., Huguet, F., Racadot, S., Thivat, E., Molnar, I., Boisselier, P., Guihard, S., Gallocher, O., …, & Lapeyre, M. (2025). Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers. JAMA Network Open, 8(12), e2549975. https://doi.org/10.1001/jamanetworkopen.2025.49975

Vancouver

Biau J, Sun X, Liem X, Faivre JC, Eker E, Blanchard P, et al. Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers. JAMA Network Open. 2025;8(12):e2549975. doi:10.1001/jamanetworkopen.2025.49975

BibTeX
@article{Biau2025,
  author = {Biau, Julian and Sun, Xushan and Liem, Xavier and Faivre, Jean-Christophe and Eker, Elife and Blanchard, Pierre and Tao, Yungan and Doré, Mélanie and Maingon, Philippe and Vulquin, Noémie and Alfonsi, Marc and Thureau, Sebastien and Huguet, Florence and Racadot, Séverine and Thivat, Emilie and Molnar, Ioana and Boisselier, Pierre and Guihard, Sébastien and Gallocher, Olivier and Dupin, Charles and Batard, Stéphanie and Bourhis, Jean and Lapeyre, Michel},
  title = {Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {12},
  pages = {e2549975},
  doi = {10.1001/jamanetworkopen.2025.49975}
}
Kostenlos starten →